UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2014
The Medicines Company
(Exact name of registrant as specified in charter)
|
Delaware |
|
000-31191 |
|
04-3324394 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
8 Sylvan Way |
|
07054 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (973) 290-6000
Not applicable.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
On November 5, 2014, The Medicines Company (the “Company”) hosted an Investor & Analyst Day. A copy of the materials presented by the Company at the Investor & Analyst Day are attached to this current report as Exhibit 99.1.
The information furnished pursuant to Item 7.01 of this current report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. As such, this information shall not be incorporated by reference into any of the Company’s reports or other filings made with the Securities and Exchange Commission. The furnishing of the information in this current report is not intended to, and does not, constitute a determination or admission by the Company that the information in this current report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibit
The following exhibit is furnished as part of this current report on Form 8-K:
Exhibit 99.1 — The Medicines Company Investor & Analyst Day Presentation.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: November 5, 2014 |
THE MEDICINES COMPANY | |
|
|
| |
|
|
By: |
/s/ Stephen M. Rodin |
|
|
Name: |
Stephen M. Rodin |
|
|
Title: |
Senior Vice President and General Counsel |